Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Apposite Capital’s partner, Allan Marchington, appointed to the board of the BIA


London, UK – 30th September 2008. Apposite Capital, the healthcare specialist investment firm, announced today that the BioIndustry Association (BIA) has elected Allan Marchington as a new member of its Board of Directors at its Annual General Meeting which took place on 25th September 2008. Allan’s appointment will be effective on 1st January 2009. In addition, Dr Clive Dix was confirmed as Chairman, and Glyn Edwards, CEO of Antisoma, was reappointed to the Board.

Allan Marchington has been a partner at Apposite Capital since its inception in 2006. Allan is a well-known entrepreneur and executive in the pharmaceuticals sector. Previously Allan was Entrepreneur in Residence at Abingworth Management which he joined from Millennium Pharmaceuticals, Cambridge, MA, USA, where he was responsible for Millennium's European activities and the company's technology investments. Prior to Millennium, he was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company that was acquired by Millennium for a substantial multiple of invested capital. Before setting up Cambridge Combinatorial, Allan worked for 7 years in a range of therapeutic areas at Pfizer, Sandwich. He has a PhD in Chemistry from the University of Liverpool.

Aisling Burnand, Chief Executive of the BIA, said:

“I would like to welcome our new Board Directors and thank those Board Directors who are standing down at the end of the year. The collective experience of our Board is extremely valuable to the BIA and their sector experience is integral to determining our strategy going forward.”

- Ends-

About Apposite Capital
www.appositecapital.com

Apposite Capital is an independent investment firm focused exclusively on Healthcare. The firm primarily invests in private companies involved in Healthcare Services and Life Sciences.

Apposite has an in-depth sector knowledge covering all aspects of the healthcare industry globally, with a unique unrivalled reach to Japan. The investment team combines complementary entrepreneurial, private equity and investment banking skills.

Apposite has built a high quality portfolio of companies in the US and Europe. The firm invests in seasoned management with a clear vision and is committed to adding value to its portfolio companies. Apposite balances its investments across all stages of company development, providing venture, development and mezzanine financings as well as buyout capital. Apposite typically invests as a lead investor and has a representation at the Board of Directors.

Created in 2006, Apposite is investing its current fund of over $200 million and is based in London, UK.

About the BIA

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.

With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members’ interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society. For further information, please go to: www.bioindustry.org

Contact:

Valerie Auffray
Investor Relations Manager
Apposite Capital
valerie.auffray@appositecapital.com
Tel: +44(0)20 7090 6383


Publisher Contact Information:

Apposite Capital
+44(0)20 7090 6383
valerie.auffray@appositecapital.com

Company profile of Apposite Capital
Past press releases of Apposite Capital.

Data


26,581
Tech investments
From our Online Data Service
17,166
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jan 17N/AIT services
Jan 17€7.4MInternet commerce
Jan 16€100.0MConsumer electronics
Jan 16€23.0MBiotechnology
Jan 15€1.2MEnergy related
Jan 15€28.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.